Clinitech Lab

Why is Clinitech Laboratory Ltd falling/rising?

As of 09-Jul, Clinitech Laboratory Ltd's stock price is at 40.00, unchanged from the previous day, but has declined 4.76% over the past week, underperforming the Sensex. Despite a positive month and strong yearly performance, the stock's year-to-date decline and erratic trading behavior contribute to its current stagnation.

As of 09-Jul, Clinitech Laboratory Ltd's stock price is currently at 40.00, showing no change from the previous day. The stock has experienced a decline of 4.76% over the past week, which is significantly worse than the Sensex's decline of only 0.98% during the same period. Additionally, the stock opened with a loss of 4.76% today, reaching an intraday low of Rs 40. <BR><BR>Despite a positive performance over the past month, where the stock rose by 5.82% compared to the Sensex's 3.82%, its year-to-date performance remains negative at -4.99%, while the Sensex has also declined by 9.95%. The stock has shown strong performance over the past year, with an increase of 18.34%, contrasting with the Sensex's drop of 8.13%. <BR><BR>Today's trading has been characterized by erratic behavior, as the stock did not trade on 5 out of the last 20 days. Furthermore, it is currently underperforming its sector by 3.15%. Although there has been a rise in investor participation, with delivery volume increasing by 100% against the 5-day average, the stock's price has not reflected this positive trend. <BR><BR>Overall, the combination of recent poor performance, significant opening losses, and underperformance relative to the sector contributes to the current stagnation in the stock price of Clinitech Laboratory Ltd.

Which are the latest news on Clinitech Lab?

What does Clinitech Lab do?

Clinitech Laboratory Ltd is a micro-cap company in the healthcare services industry, recently transitioned to a public limited status. It has a market cap of INR 9 Cr, with a P/E ratio of 21.00 and a return on equity of 4.54%.

Overview:<BR>Clinitech Laboratory Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Clinitech Laboratory Limited was incorporated as Clinitech Laboratory Private Limited in 2010. The company changed its status to Public Limited and its name to Clinitech Laboratory Limited on August 25, 2023.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 9 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 21.00<BR>Industry P/E: 60<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.18<BR>Return on Equity (ROE): 4.54%<BR>Price-to-Book: 0.93<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Clinitech Lab?

As of 10th June, Clinitech Laboratory Ltd has a market capitalization of 9.00 Cr, classified as a Micro Cap, with Shareholder's Funds of 8.83 Cr and Total Assets of 10.55 Cr reported as of March 2025. There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Clinitech Laboratory Ltd has a market capitalization of 9.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 8.83 Cr and Total Assets valued at 10.55 Cr.

Who are the peers of the Clinitech Lab?

Clinitech Lab's peers include Transgene Biotek, Adeshwar Meditex, Family Care, Vanta Bioscience, Looks Health, Dr Lalchand. Lab, Dhanvantri Jeev., Ashram Online, and Gian Lifecare. Family Care shows excellent management and growth, while Looks Health has the highest 1-year return at 85.17%, and Gian Lifecare has the lowest at -62.42%.

Peers: The peers of Clinitech Lab are Transgene Biotek, Adeshwar Meditex, Family Care, Vanta Bioscience, Looks Health, Dr Lalchand. Lab, Dhanvantri Jeev., Ashram Online, and Gian Lifecare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Family Care, while Below Average management risk is found at Adeshwar Meditex, Vanta Bioscience, Dr Lalchand. Lab, Dhanvantri Jeev., Gian Lifecare, and the rest. Growth is rated as Good at Family Care, while Below Average growth is noted for Adeshwar Meditex, Vanta Bioscience, Dr Lalchand. Lab, Dhanvantri Jeev., Gian Lifecare, and the rest. Capital Structure is Excellent at Family Care, while Good capital structure is seen at Dr Lalchand. Lab, Dhanvantri Jeev., Gian Lifecare, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Looks Health at 85.17%, while Gian Lifecare has the lowest at -62.42%. Clinitech Lab's 1-year return is 2.29%, which is significantly higher than Gian Lifecare's but lower than Looks Health's. Additionally, peers such as Dr Lalchand. Lab, Dhanvantri Jeev., and Gian Lifecare have negative six-month returns.

How has been the historical performance of Clinitech Lab?

Clinitech Lab's historical performance shows increasing net sales and total assets, but declining profitability metrics such as operating profit and net income over the past three years. Despite challenges in cash flow management, the company reported a net cash inflow of 2.00 Cr in Mar'25.

Answer:<BR>The historical performance of Clinitech Lab shows a mixed trend in financial metrics over the past three years.<BR><BR>Breakdown:<BR>Clinitech Lab's net sales increased from 6.35 Cr in Mar'23 to 6.40 Cr in Mar'24, and further to 8.23 Cr in Mar'25, indicating a positive growth trajectory. Total operating income followed a similar pattern, reaching 8.23 Cr in Mar'25. However, total expenditure also rose significantly from 4.99 Cr in Mar'23 to 7.40 Cr in Mar'25, leading to a decline in operating profit (PBDIT) from 1.36 Cr in Mar'23 to 1.06 Cr in Mar'25. Profit before tax showed a decrease from 0.86 Cr in Mar'23 to 0.55 Cr in Mar'25, while profit after tax also fell from 0.61 Cr in Mar'23 to 0.39 Cr in Mar'25. Despite these declines, earnings per share (EPS) decreased from 4.07 in Mar'23 to 1.71 in Mar'25. On the balance sheet, total assets grew from 5.88 Cr in Mar'23 to 10.55 Cr in Mar'25, with total liabilities increasing from 5.88 Cr to 10.55 Cr in the same period. The company reported a net cash inflow of 2.00 Cr in Mar'25, contrasting with previous years where cash flow from operating activities was negative. Overall, Clinitech Lab's financial performance reflects growth in sales and assets but challenges in profitability and cash flow management.

When is the next results date for Clinitech Lab?

The next results date for Clinitech Lab is 12 November 2025.

The next results date for Clinitech Lab is scheduled for 12 November 2025.

Is Clinitech Lab overvalued or undervalued?

As of August 28, 2025, Clinitech Lab is considered undervalued with a PE ratio of 11.41 and a low PEG ratio of 0.00, indicating a positive shift in its valuation grade to attractive, despite a year-to-date return of -36.6%, while outperforming the Sensex over the past month.

As of 28 August 2025, Clinitech Lab's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 11.41, an EV to EBITDA ratio of 11.57, and a ROE of 10.99%. These metrics suggest that Clinitech Lab offers a compelling investment opportunity compared to its peers.<BR><BR>In the peer comparison, Clinitech Lab's PE ratio of 11.41 stands in stark contrast to Max Healthcare's exorbitant 93.61 and Apollo Hospitals' 70.56, both of which are categorized as very expensive. Additionally, Clinitech's PEG ratio is notably low at 0.00, further supporting the undervaluation narrative. While the stock has faced challenges with a year-to-date return of -36.6%, it has outperformed the Sensex over the past month, which saw a decline of 1.00%. This performance may indicate a potential recovery and growth trajectory for Clinitech Lab.

Who are the top shareholders of the Clinitech Lab?

The top shareholders of Clinitech Lab include promoter Jyoti Jagdish Nayak with 29.57%, public shareholder Santosh Gopalkrishna Kudva with 6.2%, and individual investors collectively owning 36.28%. There is one foreign institutional investor holding 0.32%, and no mutual funds are currently invested in the company.

The top shareholders of Clinitech Lab include the promoters, who hold the majority of the shares. The promoter with the highest holding is Jyoti Jagdish Nayak, who owns 29.57% of the company. Additionally, the highest public shareholder is Santosh Gopalkrishna Kudva, holding 6.2%. Individual investors collectively own 36.28% of the shares, while there is one foreign institutional investor (FII) that holds 0.32%. There are currently no mutual funds holding shares in the company.

What is the technical trend for Clinitech Lab?

As of June 5, 2025, Clinitech Lab's trend is bearish with moderate strength, supported by bearish signals from Bollinger Bands and moving averages, despite a mildly bullish weekly MACD and some divergence in the OBV.

As of 5 June 2025, the technical trend for Clinitech Lab has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD indicates a mildly bullish signal, but this is overshadowed by bearish signals from the Bollinger Bands and moving averages on the daily timeframe. Additionally, both the weekly and monthly Dow Theory confirm a bearish outlook. The OBV shows a mildly bearish trend on the weekly, while the monthly is mildly bullish, suggesting some divergence. Overall, the negative performance over the past week and month further supports the bearish sentiment.

Has Clinitech Lab declared dividend?

No Dividend History Available